Daily Respiratory Research Analysis
Analyzed 74 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out today: a phase II trial shows cadonilimab plus chemotherapy yields promising efficacy in PD-L1-negative advanced NSCLC with cfDNA methylation predicting response earlier than imaging; a nationwide cohort quantifies a ~7-fold higher risk of pulmonary aspergillosis among tuberculosis survivors; and a randomized human exposure study finds wood smoke suppresses bronchial transcription factor activation, suggesting compromised airway immune defense.
Research Themes
- Immuno-oncology for PD-L1-negative NSCLC and early molecular response monitoring
- Post-tuberculosis lung disease and fungal complications
- Air pollution (biomass smoke) and airway immune-pathophysiology
Selected Articles
1. Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.
In PD-L1-negative advanced NSCLC, first-line cadonilimab (PD-1/CTLA-4 bispecific) plus chemotherapy achieved a 12-month PFS rate of 42.1%, ORR 66.0%, DCR 100%, and median PFS of 9.7 months with manageable safety. cfDNA methylation-based molecular response anticipated radiographic response by ~5 cycles, and baseline methylation risk stratified PFS.
Impact: Addresses a major therapeutic gap in PD-L1-negative NSCLC and introduces a practical, earlier molecular response biomarker using cfDNA methylation.
Clinical Implications: Cadonilimab plus chemotherapy could be considered in PD-L1-negative NSCLC where options are limited, and serial cfDNA methylation may guide early treatment decisions and risk stratification pending validation.
Key Findings
- 12-month PFS rate reached 42.1% (95% CI 29.6–60.0%).
- Median PFS was 9.7 months; ORR 66.0%; DCR 100.0%; median DOR 9.5 months.
- Grade ≥3 treatment-related adverse events occurred in 52.0% of patients.
- cfDNA methylation-based molecular response predicted clinical response ~5 cycles earlier than imaging.
- Baseline methylation risk (DMF scores) correlated with PFS (11.4 vs 6.9 months for low- vs high-risk).
Methodological Strengths
- Prospective phase II design with prespecified primary endpoint.
- Integration of cfDNA methylation as a quantitative early-response biomarker.
Limitations
- Single-arm, non-randomized design limits comparative inference.
- Sample size and follow-up duration not optimized for overall survival conclusions.
Future Directions: Conduct randomized controlled trials versus standard chemoimmunotherapy in PD-L1-negative NSCLC and prospectively validate cfDNA methylation-guided response adaptation.
Although immunotherapy is approved for patients with high PD-L1 expression, optimal therapeutic strategies for PD-L1-negative populations remain undefined. This study (ChiCTR2300071681) assessed the efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy in patients with PD-L1-negative advanced non-small-cell lung cancer (NSCLC). The primary endpoint, 12-month progression-free survival (PFS) rate, is 42.1% (95% CI, 29.6%-60.0%), which has reached the prespecified threshold. Secondary endpoints include a median overall survival of not reached, a median PFS of 9.7 months, an objective response rate of 66.0%, a disease control rate of 100.0%, and a median duration of response of 9.5 months. Grade ≥3 treatment-related adverse events occur in 26 (52.0%) patients. cfDNA methylation-based molecular response predicts the actual clinical response approximately 5 cycles earlier than conventional radiographic evaluation. Baseline differentially methylated fragments scores show a significant correlation with PFS, with low-risk patients demonstrating a longer median PFS compared to high-risk patients (11.4 months versus 6.9 months). Overall, first-line cadonilimab plus chemotherapy shows an encouraging efficacy with a manageable safety profile for challenging-to-treat PD-L1-negative advanced NSCLC, warranting further evaluation in controlled studies.
2. Risk of Pulmonary Aspergillosis in Tuberculosis Survivors: A Nationwide Population-based Study.
In a nationwide retrospective cohort (13,653 TB survivors; 40,959 controls; median follow-up 5.4 years), TB survivors had a markedly higher incidence of pulmonary aspergillosis (aHR 6.84). Low BMI, diabetes, connective tissue disease, and bronchiectasis independently increased risk, informing risk-based surveillance.
Impact: Quantifies a large, clinically actionable increase in aspergillosis risk after TB and identifies modifiable and comorbid risk factors to target surveillance and prevention.
Clinical Implications: Implement long-term surveillance for aspergillosis in TB survivors—especially those with low BMI, diabetes, connective tissue disease, or bronchiectasis—and consider early diagnostic imaging/serology and antifungal referral pathways.
Key Findings
- TB survivors had a higher aspergillosis incidence than controls (0.89 vs 0.09 per 1,000 person-years; p<0.001).
- Adjusted hazard ratio for aspergillosis in TB survivors was 6.84 (95% CI 3.89–12.1).
- Independent risk factors among TB survivors: low BMI (aHR 2.06), diabetes (aHR 4.45), connective tissue disease (aHR 23.19), bronchiectasis (aHR 2.55).
- Median follow-up was 5.4 years.
Methodological Strengths
- Large, nationwide cohort with matched controls and long follow-up.
- Robust multivariable adjustment identifying independent risk factors.
Limitations
- Administrative data may introduce misclassification and residual confounding.
- Lack of mycological confirmation and detailed imaging data at the individual level.
Future Directions: Prospective screening studies to define optimal diagnostic algorithms and evaluate preventive strategies (e.g., antifungal stewardship or bronchiectasis management) in high-risk TB survivors.
Survivors of tuberculosis (TB) often develop structural lung damage, including fibrosis, cavities, and bronchiectasis, which may predispose them to secondary infections such as pulmonary aspergillosis. Using data from Korea's Healthcare Big Data platform, which integrates information from the Korea National Health Insurance Service and the Korea Centers for Disease Control and Prevention, we conducted a retrospective cohort study including 13,653 TB survivors and 40,959 matched controls without a history of TB. During a median follow-up of 5.4 years, the incidence of pulmonary aspergillosis was markedly higher among TB survivors than controls (0.89 vs. 0.09 per 1,000 person-years; p < 0.001), corresponding to an adjusted hazard ratio (aHR) of 6.84 (95% confidence interval [CI], 3.89-12.1). Among TB survivors, low body mass index (aHR, 2.06; 95% CI, 1.11-3.82), diabetes mellitus (aHR, 4.45; 95% CI, 2.56-7.73), connective tissue disease (aHR, 23.19; 95% CI, 2.99-179.63), and bronchiectasis (aHR, 2.55; 95% CI, 1.08-6.04) were independently associated with pulmonary aspergillosis. These findings indicate that TB survivors are at a substantially increased risk of pulmonary aspergillosis, underscoring the need for long-term surveillance and risk-based management strategies in this high-risk population.
3. Bronchial mucosal nuclear transcription factor expression and inflammatory response in humans after exposure to wood smoke.
In a double-blind randomized crossover human exposure study (n=14), 2-hour wood smoke exposure acutely reduced nuclear translocation of AhR and p-c-jun in bronchial epithelium at 6 hours without neutrophil recruitment, contrasting with proinflammatory responses to ozone or diesel. Findings align with impaired macrophage phagocytosis from prior work, indicating compromised airway immune defense.
Impact: Provides controlled human evidence that biomass smoke may blunt early epithelial transcriptional responses, offering a mechanistic explanation for infection susceptibility in exposed populations.
Clinical Implications: Public health measures to reduce household biomass smoke exposure are reinforced; clinicians should maintain vigilance for airway infections in exposed individuals even without classic inflammatory biomarker rises.
Key Findings
- Wood smoke exposure reduced nuclear translocation of AhR and phosphorylated c-jun in bronchial epithelium at 6 hours.
- No endothelial adhesion molecule-mediated recruitment of neutrophils or other inflammatory cells into bronchial mucosa.
- Findings contrast with strong proinflammatory effects of ozone and diesel exhaust seen in prior studies.
- Together with prior evidence of cytotoxicity and impaired macrophage phagocytosis, results suggest compromised airway immune defense.
Methodological Strengths
- Double-blind, randomized crossover design with within-subject controls.
- Direct bronchial mucosal biopsies and lavage enabling tissue-level mechanistic readouts.
Limitations
- Small sample size (n=14) and short post-exposure window (6 hours).
- Healthy volunteers limit generalizability to patients with chronic lung disease.
Future Directions: Longer-term, repeated-exposure studies in susceptible populations (e.g., COPD, biomass-exposed households) to link transcriptional suppression with clinical infection outcomes and to test mitigation strategies.
BACKGROUND: Exposure to wood smoke is associated with negative respiratory health outcomes such as airway infections and development of chronic obstructive pulmonary disease (COPD). Previous controlled exposure studies in humans with bronchoscopy sampling have shown wood smoke-induced bronchial cytotoxicity and impaired macrophage phagocytosis. The present study investigated whether an early and transient acute inflammatory response, as reflected in bronchial mucosal biopsies and lavage fluids, could be detected 6 h after wood smoke exposure. METHODS: On two separate occasions, fourteen healthy participants were exposed, in a double-blind, randomised crossover design, for 2 h to filtered air and diluted wood smoke generated from incomplete wood log combustion with a mean particulate matter concentration of 409 ± 43 µg/m RESULTS: In bronchial mucosal biopsies, nuclear translocation of the transcription factors aryl hydrocarbon receptor (AhR) and phosphorylated c-jun (p-c-jun) was significantly reduced within the bronchial epithelium after wood smoke exposure compared to filtered air. There was no endothelial adhesion molecule-mediated recruitment of neutrophils or other inflammatory cells into the bronchial mucosa. CONCLUSIONS: Exposure to wood smoke from incomplete wood log combustion suppressed nuclear translocation of transcription factors and the expected inflammatory response in endobronchial mucosal biopsies at 6 h post-exposure. This contrasts to the strong proinflammatory effects of other air pollutants such as ozone and diesel exhaust. Together with previous findings of increased cytotoxicity and impaired airway macrophage phagocytosis in humans, this response may be in line with compromised immune defence and increased susceptibility to airway infections, chronic bronchitis and COPD observed in populations exposed to high levels of indoor air pollution from wood smoke.